NovoCure (NVCR 17.51, -12.26, -41.2%): Provides update on phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 trial evaluating tumor treating fields therapy in platinum-resistant ovarian cancer; did not meet its primary endpoint of overall survival (OS) at the final analysis
Boston Scientific (BSX 53.66, +2.90, +5.7%): reports ADVENT study of the FARAPULSE Pulsed Field Ablation System meets primary efficacy and safety endpointsBSX